… cancer (NSCLC) patients with activating EGFR mutations … many other selective inhibitors
against EGFR T790M that are … caused EGFR T790M tumor shrinkage in a lung cancer patient …

… EGFR downstream signalling pathways include (1) the phosphatidylinositol-3-kinase (PI3K)/protein
kinase B (AKT) pathway… (ASP8273, Astellas closed enrolment in ASP8273 studies), …

… However, promising approaches aimed to inhibit mutant K-… , the inhibition of both pathways
has led to tumour shrinkage … (AC0010), naquotinib (ASP8273) and WZ4002. They were all …

… therapy of tumors with EGFR common activating mutations (3… SCLC patients typically achieve
tumor shrinkage with the first-… treatment with ASP8273, a Japanese 3rd G EGFR-TKI (82). …

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
| Signal Transduction and Targeted Therapy … Signal Transduction and Targeted Therapy …

… to be potent inhibitors of T790M-mutant EGFR, while … *, CO-1686, HM61713 and ASP8273
excluded due to halted … , 12 patients a partial response and tumour shrinkage was seen in the …

… inhibition reduced the viability of EGFR-mutated lung cancer … resulted in dramatic tumor
shrinkage with the tumors never re-… with EGFR-TKIs gefitinib, erlotinib, afatinib, or ASP8273 were …

… to a mutated selective EGF receptor tyrosine kinase inhibitor (TKI… -selective EGFR inhibitor
with IC50 values for EGFR(L858R )and … Phase I study suggests that ASP8273 is tolerable and …

… as ASP8273, is an irreversible EGFR inhibitor targeting … to induce tumor reduction with mutant
EGFR-positive tumors … CH7233163 is a selective inhibitor for several EGFR mutants such …

… EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small-cell lung
cancer … response and stable disease), tumour shrinkage, and pharmacokinetics of lazertinib. …